Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Product, net	$ 45,954,000		$ 97,307,000
Total revenues	45,954,000		97,307,000
Costs and expenses:
Cost of sales (excluding amortization of in-licensed rights)	3,078,000		3,807,000
Research and development	34,239,000	$ 34,349,000	122,266,000	$ 117,523,000
Selling, general and administrative	28,176,000	22,184,000	90,461,000	60,812,000
Settlement and license charges	25,588,000		28,427,000
Amortization of in-licensed rights	780,000		837,000
Total cost and expenses	91,861,000	56,533,000	245,798,000	178,335,000
Operating loss	(45,907,000)	(56,533,000)	(148,491,000)	(178,335,000)
Other income (loss):
Gain from sale of Priority Review Voucher			125,000,000
Interest income (expense) and other, net	184,000	(209,000)	703,000	(478,000)
Total other income (loss)	184,000	(209,000)	125,703,000	(478,000)
Loss before income tax expense	(45,723,000)	(56,742,000)	(22,788,000)	(178,813,000)
Income tax expense	2,011,000	0	3,902,000	0
Net loss	(47,734,000)	(56,742,000)	(26,690,000)	(178,813,000)
Other comprehensive income (loss):
Unrealized gain (loss) on cash equivalents and short-term investments	26,000	(1,000)	108,000	111,000
Total other comprehensive income (loss)	26,000	(1,000)	108,000	111,000
Comprehensive loss	$ (47,708,000)	$ (56,743,000)	$ (26,582,000)	$ (178,702,000)
Net loss per share - basic and diluted	$ (0.78)	$ (1.18)	$ (0.47)	$ (3.83)
Weighted average number of shares of common stock outstanding for computing basic and diluted net loss per share	61,528	48,254	57,166	46,709